EVASPA (EVapotranspiration Assessment from SPAce) Tool: An overview

AbstractEvapotranspiration (ET) is a fundamental variable of the hydrological cycle and its estimation is required for irrigation management, water resources planning and environmental studies. Remote sensing provides spatially distributed cost-effective information for ET maps production at regional scale. We have developed EVASPA too for mapping ET from remote sensing data at spatial and temporal scales relevant to hydrological or agronomica studies.EVASPA includes several algorithms for estimating evapotranspiration and various equations for estimating the required input information (net radiation, ground heat flux, evaporative fraction…), which provides a way to assess uncertainties in the derivation of ET. The tool integrates data from various remote sensing sensors and it can be easily adapted to new sensors. To test the tool, evapotranspiration maps have been produced for the Crau-Camargue pilot site (south-eastern France), where several energy balance stations deployed in contrasted areas provide ground measurements. An overall description of the tool and first results of performance asse sment (comparison to ground data) are presented here

On the Relationship Between the Optical Emission-Line and X-ray Luminosities in Seyfert 1 Galaxies

We have explored the relationship between the [O III] $\lambda$5007 and the 2--10 keV luminosities for a sample of Broad- and Narrow-Line Seyfert 1 galaxies (BLSy1 and NLSy1, respectively). We find that both types of Seyferts span the same range in luminosity and possess similar [O III]/X-ray ratios. The NLSy1s are more luminous than BLSy1s, when normalized to their central black hole masses, which is attributed to higher mass accretion rates. However, we find no evidence for elevated [O III]/X-ray ratios in NLSy1s, which would have been expected if they had excess EUV continuum emission compared to BLSy1s. Also, other studies suggest that the gas in narrow-line regions (NLR) of NLSy1s and NLSy1s span a similar range in ionization, contrary to what is expected if those of the former are exposed to a stronger flux of EUV radiation. The simplest interpretation is that, like BLSy1s, a large EUV bump is not present in NLSy1s. However, we show that the [OIII]/X-ray ratio can be lowered as a result of absorption of the ionizing continuum by gas close to the central source, although there is no evidence that intrinsic line-of-sight absorption is more common among NLSy1s, as would be expected if there were a larger amount of circumnuclear gas. Other possible explanations include: 1) anisotropic emission of the ionizing radiation, 2) higher gas densities in the NLR of NLSy1s, resulting in lower average ionization, or 3) the presence of strong winds in the the nuclei of NLSy1s which may drive off much of the gas in the narrow-line region, resulting in lower cover fraction and weaker [O III] emission.Comment: 18 pages, including 3 figures, 2 tables. Accepted for publication in The Astrophysical Journa

Childhood lead exposure in France: benefit estimation and partial cost-benefit analysis of lead hazard control

<p>Abstract</p> <p>Background</p> <p>Lead exposure remains a public health concern due to its serious adverse effects, such as cognitive and behavioral impairment: children younger than six years of age being the most vulnerable population. In Europe, the lead-related economic impacts have not been examined in detail. We estimate the annual costs in France due to childhood exposure and, through a cost benefit analysis (CBA), aim to assess the expected social and economic benefits of exposure abatement.</p> <p>Methods</p> <p>Monetary benefits were assessed in terms of avoided national costs. We used results from a 2008 survey on blood-lead (B-Pb) concentrations in French children aged one to six years old. Given the absence of a threshold concentration being established, we performed a sensitivity analysis assuming different hypothetical threshold values for toxicity above 15 μg/L, 24 μg/L and 100 μg/L. Adverse health outcomes of lead exposure were translated into social burden and economic costs based on literature data from literature. Direct health benefits, social benefits and intangible avoided costs were included. Costs of pollutant exposure control were partially estimated in regard to homes lead-based paint decontamination, investments aiming at reducing industrial lead emissions and removal of all lead drinking water pipes.</p> <p>Results</p> <p>The following overall annual benefits for the three hypothetical thresholds values in 2008 are: €22.72 billion, €10.72 billion and €0.44 billion, respectively. Costs from abatement ranged from €0.9 billion to 2.95 billion/year. Finally, from a partial CBA of lead control in soils and dust the estimates of total net benefits were € 3.78 billion, € 1.88 billion and €0.25 billion respectively for the three hypothesized B-Pb effect values.</p> <p>Conclusions</p> <p>Prevention of childhood lead exposure has a high social benefit, due to reduction of B-Pb concentrations to levels below 15 μg/L or 24 μg/L, respectively. Reducing only exposures above 100 μg/L B-Pb has little economic impact due to the small number of children who now exhibit such high exposure levels. Prudent public policies would help avoiding future medical interventions, limit the need for special education and increase future productivity, and hence lifetime income for children exposed to lead.</p

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Abstract Background Though the Expanded Disability Status Scale (EDSS) is commonly used to assess disability level in relapsing-remitting multiple sclerosis (RRMS), the criteria defining disability progression are used for patients with a wide range of baseline levels of disability in relatively short-term trials. As a result, not all EDSS changes carry the same weight in terms of future disability, and treatment benefits such as decreased risk of reaching particular disability milestones may not be reliably captured. The objectives of this analysis are to assess the probability of confirmed disability worsening to specific EDSS milestones (i.e., EDSS scores ≥3.0, ≥4.0, or ≥6.0) at 288 weeks in the Tysabri Observational Program (TOP) and to examine the impact of relapses occurring during natalizumab therapy in TOP patients who had received natalizumab for ≥24 months. Methods TOP is an ongoing, open-label, observational, prospective study of patients with RRMS in clinical practice. Enrolled patients were naive to natalizumab at treatment initiation or had received ≤3 doses at the time of enrollment. Intravenous natalizumab (300 mg) infusions were given every 4 weeks, and the EDSS was assessed at baseline and every 24 weeks during treatment. Results Of the 4161 patients enrolled in TOP with follow-up of at least 24 months, 3253 patients with available baseline EDSS scores had continued natalizumab treatment and 908 had discontinued (5.4% due to a reported lack of efficacy and 16.4% for other reasons) at the 24-month time point. Those who discontinued due to lack of efficacy had higher baseline EDSS scores (median 4.5 vs. 3.5), higher on-treatment relapse rates (0.82 vs. 0.23), and higher cumulative probabilities of EDSS worsening (16% vs. 9%) at 24 months than those completing therapy. Among 24-month completers, after approximately 5.5 years of natalizumab treatment, the cumulative probabilities of confirmed EDSS worsening by 1.0 and 2.0 points were 18.5% and 7.9%, respectively (24-week confirmation), and 13.5% and 5.3%, respectively (48-week confirmation). The risks of 24- and 48-week confirmed EDSS worsening were significantly higher in patients with on-treatment relapses than in those without relapses. An analysis of time to specific EDSS milestones showed that the probabilities of 48-week confirmed transition from EDSS scores of 0.0–2.0 to ≥3.0, 2.0–3.0 to ≥4.0, and 4.0–5.0 to ≥6.0 at week 288 in TOP were 11.1%, 11.8%, and 9.5%, respectively, with lower probabilities observed among patients without on-treatment relapses (8.1%, 8.4%, and 5.7%, respectively). Conclusions In TOP patients with a median (range) baseline EDSS score of 3.5 (0.0–9.5) who completed 24 months of natalizumab treatment, the rate of 48-week confirmed disability worsening events was below 15%; after approximately 5.5 years of natalizumab treatment, 86.5% and 94.7% of patients did not have EDSS score increases of ≥1.0 or ≥2.0 points, respectively. The presence of relapses was associated with higher rates of overall disability worsening. These results were confirmed by assessing transition to EDSS milestones. Lower rates of overall 48-week confirmed EDSS worsening and of transitioning from EDSS score 4.0–5.0 to ≥6.0 in the absence of relapses suggest that relapses remain a significant driver of disability worsening and that on-treatment relapses in natalizumab-treated patients are of prognostic importance

22. Analyse du cycle de vie et écoconception

Depuis quelques années, de nouvelles approches scientifiques ont vu le jour pour permettre la transition vers des modes de consommation et de production durables. Parmi les méthodes proposées, se trouvent des approches basées sur un nouveau paradigme* : la « pensée cycle de vie ». Elle se définit comme une pratique de l’utilisation efficace des ressources, qui intègre la prise en compte de toutes les conséquences (environnementales, économiques, sociales…), propres à un produit ou à un servic..

La constitution de 1958 à nos jours (2ème édition)

International audienc

Tabac et sénescence cutanée (le nouveau visage du fumeur sera-t-il celui d'une femme ridée ? (étude bibliographique))

PARIS-BIUM (751062103) / SudocCentre Technique Livre Ens. Sup. (774682301) / SudocSudocFranceF